AstraZeneca PLC and Genmab A/S: A Comprehensive Revenue Analysis

AstraZeneca vs. Genmab: A Decade of Revenue Growth

__timestampAstraZeneca PLCGenmab A/S
Wednesday, January 1, 201426095000000850385000
Thursday, January 1, 2015247080000001133041000
Friday, January 1, 2016230020000001816122000
Sunday, January 1, 2017224650000002365436000
Monday, January 1, 2018220900000003025137000
Tuesday, January 1, 2019243840000005366000000
Wednesday, January 1, 20202661700000010111000000
Friday, January 1, 2021374170000008482000000
Saturday, January 1, 20224435100000014595000000
Sunday, January 1, 20234581100000016474000000
Loading chart...

Unleashing insights

AstraZeneca PLC vs. Genmab A/S: A Decade of Revenue Growth

In the ever-evolving pharmaceutical industry, AstraZeneca PLC and Genmab A/S have demonstrated remarkable revenue trajectories over the past decade. From 2014 to 2023, AstraZeneca's revenue surged by approximately 75%, reaching its peak in 2023. This growth reflects the company's strategic focus on innovation and expansion in emerging markets. Meanwhile, Genmab A/S, a leader in antibody therapeutics, experienced an impressive revenue increase of nearly 1,800% during the same period, underscoring its successful product pipeline and strategic partnerships.

Key Insights

  • AstraZeneca's Steady Climb: Despite a modest start in 2014, AstraZeneca's revenue consistently grew, with a notable jump of 68% from 2020 to 2023.
  • Genmab's Meteoric Rise: Starting with a modest revenue in 2014, Genmab's growth trajectory was exponential, particularly between 2019 and 2023, where it more than tripled.

These trends highlight the dynamic nature of the pharmaceutical sector, where innovation and strategic alliances drive success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025